Secondary acute myelogenous leukemia following safe exposure to etoposide

Journal of Clinical Oncology

Volumn 15, Issue 4, 1997, Pages 1583-1586

  Stine, K C ^a   Saylors, Robert L ^a   Sawyer, Jeffrey R ^a   Becton, David L ^a  

^a ARKANSAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; DOXORUBICIN; ETOPOSIDE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CASE REPORT; CLINICAL PRACTICE; DISEASE ASSOCIATION; DOSE RESPONSE; FEMALE; FOLLOW UP; HEMOPHAGOCYTIC SYNDROME; HIGH RISK POPULATION; HODGKIN DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; TREATMENT PLANNING;

EID: 0030944285     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.4.1583     Document Type: Article

References (17)

1. Rivera GK, Pui CH, Santana VM, et al: Epipodophyllotoxins in the treatment of childhood cancer. Cancer Chemother Pharmacol 34:S89-95, 1994
2. Nichols CR, Breeden ES, Loehrer PJ, et al: Secondary leukemia associated with a conventional dose of etoposide: Review of serial germ cell tumor protocols. J Natl Cancer Inst 85:36-40, 1993
3. Ladisch S, Gadner H: Treatment of Langerhans cell histiocytosis - Evolution and current approaches. Br J Cancer 23:s41-46, 1994
4. Su IJ, Wang CH, Cheng AL, et al: Hemophagocytic syndrome in Epstein-Barr virus-associated T-lymphoproliferative disorders: Disease spectrum, pathogenesis, and management (review). Leuk Lymphoma 19:401-406, 1995
5. Pui CH, Behm FG, Raimondi SC, et al: Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med 321:136-142, 1989
6. Pui CH, Relling MV, Behm FG, et al: L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins. Leukemia 9:1680-1684, 1995
7. Kobayashi K, Ratain MJ: Pharmacodynamics and long-term toxicity of etoposide. Cancer Chemother Pharmacol 34:S64-68, 1994
8. Winick NJ, McKenna RW, Shuster JJ, et al: Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol 11:209-217, 1993
9. Bajorin DF, Motzer RJ, Rodriguez E, et al: Acute non-lymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. J Natl Cancer Inst 85:60-62, 1993
10. Nichols CR, Breeden ES, Loehrer PJ, et al: Secondary leukemia associated wtih a conventional dose of etoposide: Review of serial germ cell tumor protocols. J Natl Cancer Inst 85:36-40, 1993
11. Leventhal BG, Donaldson SS: Hodgkin's disease, in Pizzo PA, Poplack DG (eds): Principles and Practice of Pediatric Oncology (ed 1). Philadelphia, PA, Lipincott, 1989, pp 457-476
12. Henry-Amar M, Deitrich P-Y: Acute leukemia after the treatment of Hodgkin's disease. Hematol Oncol Clin North Am 7:369-388, 1993
13. Richards MS, Waxman JH, Man T, et al: EVA treatment for recurrent or unresponsive Hodgkin's disease. Cancer Chemother Pharmacol 18:51-53, 198.
14. Zulian GB, Mermillod B, Alberto P: ABEP as primary chemotherapy for Hodgkin's disease. Eur J Cancer 28:1727-1729, 1992
15. Ladisch S, Gadner H, Arico M, et al: LCH-I: A randomized trial of etoposide versus vinblastine in disseminated Langerhans cell histiocytosis. Med Pediatr Oncol 23:107-110, 1994
16. Stewart DJ, Nundy D, Maroun JA, et al: Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide. Cancer Treat Rep 69:269-273, 1985
17. Nichols CR: The role of etoposide therapy in germ cell cancer (review). Semin Oncol 19:72-77, 1992